T-cell Lymphoma Patient Story: Jennifer Brennan | Massachusetts General Hospital
Discover the story of Jennifer Brennan, who turned to cutting-edge cancer treatment from a highly specialized expert for her peripheral T-cell lymphoma.
Discover the story of Jennifer Brennan, who turned to cutting-edge cancer treatment from a highly specialized expert for her peripheral T-cell lymphoma.
Researchers found that a nanovaccine can be used to treat a rare form of melanoma.
Researchers used a unique 3D microfluidic model of tumors to investigate the mechanisms of treatment resistance to CAR-T cells.
After a diagnosis of non-small cell lung cancer, Flora McCoy-Greene sought the latest treatment from an integrated cancer care team at Mass General. Read her story.
Shadmehr (Shawn) Demehri, MD, PhD, of the Department of Dermatology and Center for Cancer Immunology at Massachusetts General Hospital, is the corresponding author of a paper published in Cancer Cell, “Commensal papillomavirus immunity preserves the homeostasis of highly mutated normal skin.”
Dan G. Duda, DMD, PhD, of the Edwin L. Steele Laboratories for Tumor Biology and Department of Radiation Oncology at Massachusetts General Hospital, is the corresponding author of a paper published in Cancer Immunology Research, “Combination CXCR4 and PD1 Blockade Enhances Intratumoral Dendritic Cell Activation and Immune Responses Against Hepatocellular Carcinoma.”
Massachusetts General Hospital has received a transformational gift of $100 million from entrepreneur, philanthropist, and proud Bostonian, Herb Chambers in support of a new state-of-the-art building designed to meet the growing demand for world-class cancer care.
Discover how a new rapid test developed at Mass General Brigham is enabling doctors to diagnose brain tumors faster, including Rohan’s high-grade glioma.
The 2024 class of awardees will receive more than $6 million in funding to accelerate groundbreaking cancer research.
The researchers found that damage to the heart is driven by a different immune response than the anti-tumor one, suggesting that this serious complication could one day be managed without halting cancer therapy.
An integral part of one of the world’s most distinguished academic medical centers, Mass General Cancer Center is among the leading cancer care providers in the United States.